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Summary
To assess sources of variability in platelet function tests in normal subjects, 64 healthy young 
adults were tested on 2–6 occasions at 2 week intervals using 4 methods: platelet aggregation 
(AGG) in platelet-rich plasma (PRP) in the Bio/Data PAP-4 Aggregometer (BD) and Chrono-Log 
Lumi-Aggregometer (CL); and AGG in whole blood (WB) in the CL and Multiplate Platelet 
Function Analyzer (MP), with ATP release (REL) in CL-PRP and CL-WB. Food and medication 
exposures were recorded prospectively for 2 weeks prior to each blood draw. At least one AGG 
abnormality was seen in 21% of 81 drug-free specimens with CL-PRP, 15% with CL-WB, 13% 
with BD-PRP, and 6% with MP-WB, increasing with inclusion of REL to 28% for CL-PRP and 
30% for CL-WB. Epinephrine AGG and REL were significantly reduced in males (P<0.0001). 
Ristocetin AGG and collagen and thrombin REL were significantly reduced in Blacks (P<0.0001). 
One-third of specimens drawn following flavonoid-rich food exposures had aberrant results, 
compared to 8.5% of specimens without such exposures (P=0.0035). PRP tests had less intra-
individual variation than WB tests. Gender, race, diet, and test system affected results of platelet 
function testing in healthy subjects, suggesting caution when interpreting the results of platelet 
function testing in patients.
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Measurement of platelet function in vitro is the primary clinical method used for the 
diagnosis of an inherited or acquired platelet function defect in a patient with excessive 
bleeding, although specific receptor, granule, or DNA studies are often used for 
confirmation. Light transmission aggregometry (LTA) in platelet-rich plasma (PRP), which 
has been the gold standard for platelet function testing for fifty years, measures the change 
in optical density produced when platelets form aggregates in fluid phase. Abbreviations 
used are defined in Table I. More recently, the simultaneous measurement of adenosine 
triphosphate (ATP) release as an indicator of platelet activation and granule secretion has 
been added. Impedance aggregometry allows measurement of aggregation and ATP release 
in whole blood (WB); it requires that platelets first adhere to a pair of electrodes and then 
form stationary aggregates which increase the resistance across the electrode gap. There 
have been few direct comparisons of the various measurement systems available for 
diagnosis of platelet function defects (Ingerman-Wojenski et al, 1983; Ingerman-Wojenski 
and Silver, 1986; Riess et al, 1986; Podczasy et al, 1997; Seyfert et al, 2007).
In clinical practice, it is common to test a group of “normal” subjects to set reference ranges 
for response to specific agonists and to test an individual normal subject with each patient 
tested to verify appropriate function of the test system (Christie et al, 2008; Hayward et al, 
2010; Cattaneo et al, 2013). Numerous drugs have been documented to affect aggregation 
and ATP release (Rao, 2007). In addition, certain foods, alcohol, caffeine, and smoking have 
been reported to have effects. Foods rich in flavonoids, such as chocolate, red wine, and tea 
have been particularly implicated (Pearson et al, 2005; Holt et al, 2005). Certain flavonoids 
have been shown to inhibit platelet signaling pathways through binding to the thromboxane 
A2 receptor (Guerrero et al, 2004). In clinical platelet function testing, use of medications is 
usually considered (Christie et al, 2008; Hayward et al, 2010; Cattaneo et al, 2013); the 
impact of other exposures has not been evaluated.
In a recent study of women with menorrhagia, using a standardized instrument and protocol 
for aggregation and ATP release testing at 6 sites, we found 20% of 169 control subjects 
collected for reference range determination to be abnormal with arachidonic acid alone 
(Miller et al, 2011). This led us to attempt to define the degree and sources of variation in an 
unselected group of normal subjects studied over time using four different test systems with 
prospective collection of exposure data.
Methods
Subjects
Subjects were recruited from among students and employees at Emory University in Atlanta. 
Each completed a questionnaire on history of bleeding symptoms and chronic disease. Those 
with no history of excessive bleeding or diagnosed chronic disease were tested for 
coagulation parameters as previously described (Miller et al, 2011). All subjects had normal 
coagulation function except one subject with decreased factor XII, who was not excluded. 
The 64 enrolled subjects ranged in age from 18–35 and included 30 males and 34 females. 
They self-identified their ethnicities as 34 (53%) White non-Hispanic, 22 (34%) Black non-
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Hispanic, 3 (5%) Asian, 2 (3%) White Hispanic, and 3 (5%) other. The study was conducted 
with the approval of the Institutional Review Boards of Emory University and the CDC. 
Written informed consent was obtained from all participants.
Food and Medication Data Collection
Data were collected prospectively on daily drug, food, and alcohol intake and illness through 
self-recorded standardized diaries which were collected prior to each blood draw and 
reviewed after testing was concluded. Each specimen was scored as positive or negative for 
intake of drugs other than oral contraceptives and multi-vitamins within the 2 weeks prior to 
specimen collection. No subject began or discontinued oral contraceptives during the study. 
Alcohol and flavonoid intake was scored as positive or negative for two time periods: 
morning exposure within 6 hours of blood draw and evening exposure within 12–18 hours 
of blood draw. The list of flavonoid-rich foods was compiled from the literature (Pearson et 
al, 2005; Holt et al, 2005) and included cocoa, chocolate, tea, grapes and grape products, 
fish, onions, garlic, broccoli, apples, citrus fruits, nuts, peanuts, soy, and red, blue, and 
purple berries.
Platelet Function Tests
Blood was collected into evacuated siliconized glass tubes (Becton Dickinson, Franklin 
Lakes, NJ) containing 3.2% sodium citrate in a ratio of 1:9 with blood and maintained at 
room temperature. For PRP, blood was centrifuged at 22°–25°C for 8 minutes at 200 × g. 
After transfer of two-thirds of PRP with a plastic pipette to a polypropylene tube, the 
remaining PRP was centrifuged at 22°–25°C for 20 minutes at 1,600 × g to produce platelet-
poor plasma (PPP), which was transferred with a plastic pipette to another polypropylene 
tube. PRP was standardized to a platelet count of 250 × 109 platelets L−1 by addition of PPP. 
For WB testing, whole blood was diluted with an equal volume of 0.9%NaCl.
LTA was measured in PRP using a BioData Platelet Aggregation Profiler, Model PAP-4 
(BD) (BioData Corp.) and a Chrono-Log platelet lumi-aggregometer Model 560-CA (CL) 
(Chrono-Log Corp, Haverton, PA, USA) by change in optical density and expressed as % 
maximal aggregation. WBA was measured by change in impedance and expressed as ohms 
in the CL and in aggregation units (AU) in the Multiplate analyzer (MP) (Dynabyte GmbH, 
Munich, Germany). In CL-PRP and CL-WB, REL was measured by luminescence using 
luciferin-luciferase reagent (Chrono-Log Corp.) added at a ratio of 50 microliters (μL) to 
450 μL PRP or 100 μL to 900 μL diluted WB. REL was calculated by comparison of peak 
luminescence recorded from the subject sample with that of a 2 μM ATP standard (Chrono-
Log Corp) and expressed in μmoles (μM). Reactions were initiated by the addition of 
agonists to produce the final concentrations recommended by the manufacturers, as shown 
in Table II.
Statistical Methods
Distributions were checked for normality by the D’Agostino and Pearson omnibus normality 
check. Multivariate analysis was performed for each method and agonist using gender and 
race. A P-value was calculated for multiple comparisons by the Bonferroni correction. For 
56 comparisons at a cut-off of 0.025, a P-value of <0.0004 was required to achieve 
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significance. Coefficient of variation (CV) was calculated for each subject with four or more 
specimens for each agonist and method. Reference ranges were calculated with a lower limit 
of 2.5 percentile and upper limit of 97.5 percentile using results from the first blood draw on 
each subject with no drugs other than oral contraceptives and multi-vitamins reported during 
the previous two weeks. Chi-square and Fisher’s exact test were used for comparisons. 
Statistical analysis was carried out using SAS Version 9.2 (SAS Institute, Cary, NC, USA) 
and GraphPad Prism 5 (GraphPad Software, Inc., LaJolla, CA, USA).
Results
Platelet aggregation was performed on the same blood specimen by each of four methods: 
LTA using platelet-rich plasma (PRP) in two instruments, one with simultaneous 
measurement of ATP release (REL), and WBA in two instruments, one with simultaneous 
measurement of REL. Key findings are summarized in Table III.
Specimen characteristics
Sixty-four subjects were studied at two-week intervals over a three month period. A total of 
349 specimens were tested, an average of 5.4 specimens per subject. Subjects were not 
asked to abstain from drug use but were asked to record drugs and foods ingested during the 
two-week period prior to each blood draw. Exposure to drugs was reported for 217 of 349 
specimens (62.2%), 59 (16.9%) with drugs known to affect platelet function. All subjects 
reported drug use prior to at least one specimen. Specimens with a single drug exposure 
included 35 with ibuprofen, 10 with acetaminophen, 7 with acetylsalicylic acid, and 5 with 
loratadine. A total of 162 specimens had multiple drug exposures. Results on specimens 
with drug exposures will be reported in a separate publication.
A total of 129 specimens from 41 subjects with no drug exposure reported in the previous 
two weeks other than oral contraceptives or multi-vitamins were classified as drug-free. 
Characteristics of these subjects were similar to those of the entire study group. Seven 
specimens from 4 subjects with platelet counts below 150 × 109 L−1 were excluded from 
analysis, leaving 122 drug-free specimens. Distributions of test results for these specimens 
are shown in Figure 1.
Evaluation of test profiles
Reference ranges for each test were calculated using the first drug-free specimen from each 
individual (Table IV). The remaining 81 drug-free specimens were used as a test group. The 
profile of tests from a single method, excluding ristocetin, was evaluated for each specimen 
(Table V). For REL in CL-PRP, ADP and EPI results were excluded, because their reference 
ranges included zero. The numbers of profiles with one or more abnormal AGG 
measurements were 21% for CL-PRP, 15% for CL-WB, 13% for BD-PRP, and 6% for MP-
WB. When REL was included, 28% of CL-PRP and 30% of CL-WB profiles had at least 
one abnormality. If an abnormality with 2 or more agonists was required to consider a 
profile as abnormal, as suggested by Hayward et al (2009), AGG profiles were abnormal in 
8.6% of CL-PRP, 3.7% of CL-WB, 1.7% of BD-PRP, and no MP-WB profiles, and profiles 
combining AGG and REL were abnormal in 9.9% (CL-PRP) and 13.6% (CL-WB).
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Effects of race and gender
To investigate sources of the variability observed, a multivariate analysis was performed on 
the 122 drug-free specimens using the variables race and gender and a P-value adjusted for 
multiple comparisons. EPI aggregation in CL-PRP and BD-PRP and REL in CL-PRP were 
significantly reduced in males (P<0.0001) (Figure 2). Blacks had significantly more 
aggregation than Whites using ADP in CL-WB (P=0.0001) and significantly less REL using 
collagen and thrombin in PRP and WB and AA in WB (P<0.0001). Ristocetin agglutination 
in Blacks was significantly lower than in Whites in CL-PRP (P<0.0001) (Figure 3) but not 
in BD-PRP or either WB system. No significant gender or race differences were seen using 
MP-WB.
Ristocetin response
Platelet response to ristocetin varied by instrument (Figure 1A–D, Figure 3), with BD-PRP 
showing similar medians at all concentrations. Because of these results, a further study was 
performed using additional concentrations on a new panel of 7 healthy control subjects 
(Figure 4). In CL-PRP, median agglutination dropped to near zero at 1.00 mg mL−1 but in 
BD-PRP was strong at 0.75 mg mL−1. At 0.50 mg mL−1, a concentration often used to 
detect von Willebrand disease Type 2B (VWD2B), CL-PRP showed little response (range 
0–2%), while BD-PRP continued to show a median agglutination of 10% (range 0–90%).
Intra-individual variation
47gures 5–7 show variation in individual test results over time by subject. To assess intra-
individual variation, a coefficient of variation (CV) for each subject with four or more 
specimens was calculated by agonist and method (Table VI). For PRP aggregation, median 
CVs were below 15% with collagen, AA, ADP, and EPI using both instruments. For WB 
aggregation, median CVs were between 15 and 30%. REL showed the greatest intra-
individual variation. Eighteen subjects had large CVs due to extremely low results on 
individual specimens. When these diverged from results on the subject’s other specimens, as 
illustrated by open circles in Figures 5–7, they were termed “aberrant” specimens.
Effect of food exposures
The histories of all subjects were examined for reported illness or intake of flavonoid-rich 
foods or alcohol prior to each specimen. Of 75 specimens drawn after flavonoid-rich food 
exposures, 24 (32.0%) had aberrant results, compared to 4 of 47 specimens (8.5%) without 
such exposures (P=0.0035). The distribution of exposures was significantly different 
between the aberrant and non-aberrant specimens (P<0.0001) (Table VII). Of 28 specimens 
with aberrant results, 24 (85.7%) were drawn after flavonoid-rich food intake within 18 
hours, compared to 51/94 (54.3%) with consistent results (P=0.0035). Exposure within 1–6 
hours with or without earlier exposure characterized 19/94 specimens (20.2%) with non-
aberrant results and 15/28 (53.6%) with aberrant results (P=0.0004). No other alcohol intake 
or illnesses were reported in the aberrant group. The tests affected and the specific foods 
consumed are shown in Table VIII.
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Guidelines for platelet function testing (Christie et al, 2008; Hayward et al, 2010; Cattaneo 
et al, 2013) stress the importance of insuring that the patient and normal controls have not 
taken drugs influencing platelet function. Clinical and Laboratory Standards Institute 
guidelines also recommend that the patient be fasting (Christie et al, 2008). The 
characteristics of the normal subjects for reference range definition and daily controls are 
not otherwise defined. Most clinical laboratories rely on a group of proven donors who have 
demonstrated normal platelet function on previous occasions. Repeated study of 5 such 
subjects with LTA showed good reproducibility over a 2 year period (Hevelow et al, 2007). 
Repeated WBA in 7 subjects over 5 years, however, showed abnormal results on one-third 
of 86 studies (Refaii et al, 2010). We tested 64 unselected healthy subjects, finding striking 
differences that must be considered in interpretation of patient results.
Abnormal results in a control subject are often ascribed to the subject having forgotten that 
they took medication. To improve on simple recall, we prospectively collected exposure 
data. All subjects had drug exposure on at least one specimen; more than 60% of specimens 
followed some drug exposure. Although only 17% of exposures were to drugs known to 
affect platelet function, we excluded all in order to focus on other sources of variability. To 
mimic the clinical situation, we used the first drug-free specimen from each subject to 
calculate reference ranges by non-parametric methods, including 95% of the normal 
population, as recommended (Hayward et al, 2008), and used the 81 remaining drug-free 
specimens as a test group. Diagnosis of platelet function disorders involves a panel of tests, 
ranging from at least 5 tests when measuring aggregation alone to a total of 10 when both 
aggregation and release are measured. The chance that a single test result will fall below a 
2.5 percentile cut-off is 12.5% for an aggregation profile using 5 agonists and approaches 
25% for a profile including both aggregation and release. Our findings that 6–21% of 
aggregation profiles and 28–30% of profiles measuring both aggregation and release were 
abnormal are close to that expectation. The strategy suggested to reduce the number of false 
positive profiles by requiring abnormality with >1 agonist to classify a profile as abnormal 
(Hayward et al, 2009) is effective; however, it would exclude patients with a true bleeding 
disorder affecting response to a single agonist. In spite of the statistical expectation of a 
large number of false positive tests, the frequency of specimens with minimal aggregation 
and absent release among healthy subjects is concerning.
Females have been observed to have greater aggregation than males in some studies 
(Johnson et al, 1975; Meade et al, 1985; Silver et al, 1993; Becker et al, 2006) but not in 
others (Beyan et al, 2006; Seyfert et al, 2007; Rubak et al, 2012). Here, only epinephrine 
showed a gender difference. The number of abnormalities seen in healthy subjects using a 
relatively high concentration of epinephrine (10 μM) in two different instruments makes one 
question its utility for diagnosis. Although it is included on recommended agonist panels 
(Hayward et al, 2009; Dawood et al, 2012; Cattaneo et al, 2013), we believe that its use in 
the initial screening panel may lead to misdiagnosis, particularly in males.
Ristocetin response showed a significant race difference. A single nucleotide polymorphism 
in von Willebrand factor, D1472H, which is common in Blacks, interferes with ristocetin 
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binding to von Willebrand factor and falsely lowers ristocetin cofactor (Flood et al, 2010). 
DNA was not available on our subjects to investigate this possibility. The race difference 
was evident only in CL-PRP. BD-PRP and the WB systems did not show this difference. 
Black subjects also showed decreased release with collagen and thrombin in PRP and WB 
and with AA in WB. These differences might also be due to common genetic variants.
Subjects who consumed flavonoid-rich foods prior to testing were significantly more likely 
to show results differing from their usual pattern than those without such consumption. 
Studies on the effects of foods on platelet function have focused primarily on their potential 
long-term use in the prevention of cardiovascular disease and have been conducted after 
exposure for 1–4 weeks (Pearson et al, 2005; Holt et al, 2005). Flavonoids, components of 
such common foods as chocolate, tea, red wine, and beer, have been most extensively 
studied. Black tea (Wolfram et al, 2002) and chocolate (Innes et al, 2003) have been 
demonstrated to inhibit LTA. Chocolate (Murphy et al, 2003) and grape products, including 
red wine and grape juice (Keevil et al, 2000; Pignatelli et al, 2002), have shown an effect on 
WBA. Few studies have assessed how rapidly these effects occur and their persistence. 
Chocolate prolonged the Platelet Function Analyzer-100 closure time within 4–6 hours 
(Murphy et al, 2003). Red wine retained an effect at 12 hours post consumption (Pignatelli 
et al, 2002). In this study, more flavonoid-rich foods were consumed in the evening, but 
those with aberrant results most often had both morning and evening exposures. These data 
suggest that a morning fast prior to blood draw is not sufficient to eliminate the effect of 
inhibitory foods; an abstention from specific foods of 24 hours may be required to eliminate 
their effect. Other studies have shown no effect of eating breakfast (Stegnar et al, 2010) or 
lunch (Silver et al, 1993) prior to LTA, but neither considered the intake of specific foods. 
Our study was limited by the large number of specimens excluded due to drug exposure and 
the complexity of the dietary information collected. Flavonoid-rich foods are common and 
often consumed together. Longitudinal studies will be required to determine the timing and 
magnitude of food effects on clinical platelet function testing.
The test systems used vary in basic mechanism, type of specimen, and the specific 
proprietary reagents provided as agonists. The BD-PRP system showed the least intra-
individual variation over time. Both WB systems showed more variability than PRP, 
perhaps due to standardization of the platelet count in PRP. The MP-WB system produced 
the fewest abnormal results in these healthy subjects. CL-PRP and CL-WB results, using the 
same instrument and reagents, were similar; however, in the CL-PRP system, no ATP 
release was detected on 6.6% of AA, 8.2% of ADP, and 13.1% of EPI tests, preventing 
calculation of a lower limit of the reference range. Exclusion of such low results from 
reference range calculations and yet considering them to be diagnostic in patients is not an 
acceptable practice. Overall, addition of ATP release measurements to aggregation profiles 
increased the number of abnormal findings in healthy subjects.
The panels of agonists and concentrations used (Table II) were those recommended by the 
manufacturers at the time of the study. They are similar but not identical to the 
recommendations published more recently (Dawood et al, 2012; Cattaneo et al, 2013). 
Reagent formulations vary by manufacturer, and this may contribute to the differences 
observed among the systems tested. BD-PRP showed less variability than CL-PRP with 
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different ristocetin concentrations. From this study, it could not be determined if the BD 
system can detect clinically important differences in ristocetin response, such as that seen in 
VWD2B. In VWD2B, aggregation with low ristocetin concentrations is expected to be 
increased over the minimal response usually seen in normal individuals; however, normal 
subjects had up to 90% aggregation with 0.50 mg/mL ristocetin in the BD system, 
suggesting that it might be difficult to identify VWD2B with this system.
We conclude that gender, race, diet, and test system affect results of platelet function testing 
in healthy subjects and that these differences should be considered when interpreting results 
in patients referred for evaluation of bleeding. Epinephrine and ristocetin are particularly 
problematic; abnormal results seen with either of these agonists alone may reflect population 
variation and should be interpreted cautiously. Exclusion of flavonoid-rich foods from the 
diet for 24 hours prior to testing may decrease false positive results. While it might be 
presumed that the systems with the least intra-individual variability and the fewest false-
positive results would be the best choice for patient testing, increased specificity often 
results in decreased sensitivity. A similar method comparison using patients with known 
platelet function defects would be required to determine whether the methods showing the 
least variability retain sufficient sensitivity for detection of mild platelet defects and whether 
release measurements, which decrease specificity, add appreciably to diagnostic efficacy. 
Because of the high rate of abnormal results observed in normal individuals, confirmation of 
all abnormal results by demonstrating the reproducibility of the defects in a different 
specimen, along with specific receptor, granule, or DNA studies are needed to ensure 
accurate diagnosis and avoid incorrectly labeling patients as having an abnormality of 
platelet function.
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Platelet aggregation and ATP release (REL) in drug-free subjects using collagen (COLL), 
arachidonic acid (AA), adenosine diphosphate (ADP), epinephrine (EPI), ristocetin (RIST), 
and thrombin (THROMB) in platelet-rich plasma (PRP) (A, B, E) or whole blood (WB) (C, 
D, F) in BioData system (BD), ChronoLog system (CL), and Multiplate system. * not 
normally distributed
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Gender differences in response to epinephrine in platelet-rich plasma. A. BioData system. B. 
Chrono-Log system aggregation. C. ATP release. The bar is placed at the median.
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Race differences in aggregation with ristocetin at different concentrations (mg mL−1) in 
BioData (left) and Chrono-Log (right) systems. The bar is placed at the median.
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Comparison of median platelet aggregation to various concentrations of ristocetin in the 
BioData and Chrono-Log systems among 7 healthy subjects.
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Platelet aggregation in platelet-rich plasma (PRP) from drug-free subjects in the Chrono-Log 
(CL) and BioData (BD) systems. Dashed lines represent reference ranges (2.5–97.5 
percentiles) from Table IV. Aberrant specimens are shown as open circles.
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Platelet aggregation in whole blood (WB) from drug-free subjects in the Chrono-Log (CL) 
and Multiplate (MP) systems. Dashed lines represent reference ranges (2.5–97.5 percentiles) 
from Table IV. Aberrant specimens are shown as open circles.
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Platelet ATP release in platelet-rich plasma (PRP) and whole blood (WB) from drug-free 
subjects in the Chrono-Log system. Dashed lines represent reference ranges (2.5–97.5 
percentiles) from Table IV. Aberrant specimens are shown as open circles.
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BD Bio/Data PAP-4 Aggregometer
BD-PRP PRP aggregation in the Bio/Data PAP-4 Aggregometer
CL Chrono-Log Lumi-Aggregometer
CL-PRP PRP aggregation in the Chrono-Log Lumi-Aggregometer
CL-PRP REL ATP release in PRP in the Chrono-Log Lumi-Aggregometer
CL-WB WB aggregation in the Chrono-Log Lumi-Aggregometer
CL-WB REL ATP release in WB in the Chrono-Log Lumi-Aggregometer
CV Coefficient of variation
COLL Collagen
EPI Epinephrine
LTA Light transmission aggregometry
MP Multiplate Platelet Function Analyzer





TRAP Thrombin receptor activating peptide
VWD2B von Willebrand disease type 2B
WB Whole blood
WBA Whole blood aggregometry
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Table II
Final concentration of agonists by instrument and method (PRP=platelet-rich plasma, WB=whole blood)
Reagent
Method
BioData PRP Chrono-Log PRP Chrono-Log WB Multiplate WB
ADP 20 μM 10 μM 20 μM 6.5 μM
Arachidonic Acid 0.5 mM 0.5 mM 0.5 mM 0.5 mM
Collagen 1.9 μg mL−1 2 μg mL−1 2 μg mL−1 3.2 μg mL−1
Epinephrine 10 μM 10 μM -- --
Thrombin -- 1 U mL−1 1 U mL−1 --
TRAP* -- -- -- 32 μM











Thrombin receptor activating peptide
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Table V
Test profiles by method with tests scored as abnormal if outside the reference ranges and profiles scored as 




Number Abnormal n (%)
1 Agonist >1 Agonist
Aggregation Alone: Chrono-Log PRP 81 17 (21) 7 (8.6)
Chrono-Log WB 81 12 (15) 3 (3.7)
BioData PRP 60 8 (13) 1 (1.7)
Multiplate WB 49 3 (6.1) 0
ATP Release Alone: Chrono-Log PRP 81 15 (19) 4 (4.9)
Chrono-Log WB 81 20 (25) 8 (10.0)
Aggregation and ATP Release: Chrono-Log PRP 81 23 (28) 8 (9.9)
Chrono-Log WB 81 24 (30) 11 (13.6)
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Table VII
Exposures to flavonoid-rich foods prior to blood draw for specimens with aberrant results and non-aberrant 
results
Exposures Non-aberrant Results (94 specimens) n (%)
Aberrant Results (28 
specimens) n (%) Significance
Morning of blood draw only* 9 (9.6) 1 (3.6)
Evening before blood draw only** 32 (34.0) 9 (32.1) χ2=23.50,
Both Morning and Evening 10 (10.6) 14 (50.0) P<0.0001
None 43 (45.7) 4 (14.3)
All Exposures within 18 hours 51 (54.3) 24 (85.7) P=0.0035
Exposures within 6 hours with or without earlier exposure 19 (20.2) 15 (53.6) P=0.0004
*
Within 1–6 hours of blood draw
**
Within 12–18 hours of blood draw
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